Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD.

Tune in as experts Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, and Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, provide insights into current and emerging treatment approaches for acute and chronic GvHD, discussing the advent of new therapies. Following this, you'll learn about the importance of the gut microbiome in the severity of GvHD and how this can be manipulated to improve patient outcomes.

In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help healthcare professionals with the treatment and management of cancer therapy-related cardiovascular toxicities (CTR-CVT).

In this podcast, Daniel Lenihan, MD, FACC, Saint Francis Healthcare System, Cape Girardeau, MO, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, unravel the critical relevance of cardio-oncology, stressing the significance of multidisciplinary teams (MDTs) and the application of the ESC 2022 guidelines. Discussing their experiences from different healthcare institutions across the globe, the experts underscore the importance of cooperation between cardiologists and hematologists as they navigate difficult medical decisions for patients with specific complications.

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field.

In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss novel technologies being explored to risk stratify individuals with SMM and MGUS. Following this, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, Kwee Yong, PhD, FRCP, FRCPath, University College London, London, UK, and Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, discuss the possibility of early interception in SMM, highlighting ongoing trials in the field. This episode is part of our podcast series from the 2024 Intercepting Blood Cancers (IBC) Workshop, which was held in Lisbon, Portugal.